NRX Pharmaceuticals, Inc. — Form 8-K
Filed September 15, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
NRx Pharmaceuticals received written notice from FDA's Office of Generic Drugs that its ANDA amendment for preservative-free ketamine (NRX-100) was reclassified from Major to Minor Amendment, eliminating the need for substantial FDA resource expenditure. The new GDUFA goal date is November 10, 2026. This reclassification accelerates the approval timeline for a drug addressing a stated shortage.
Why this rating
Regulatory acceleration on lead asset substantially de-risks path to approval for ~$57M market-cap biotech; meaningful near-term value catalyst, though still clinical-stage with approval not guaranteed.
Price action (we called it positive)
at our read pending | +10 min pending | +30 min pending | +1 hr pending | +4 hrs pending |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from September 15, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.